0001209191-23-045875.txt : 20230815
0001209191-23-045875.hdr.sgml : 20230815
20230815164607
ACCESSION NUMBER: 0001209191-23-045875
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230810
FILED AS OF DATE: 20230815
DATE AS OF CHANGE: 20230815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Szela Mary T
CENTRAL INDEX KEY: 0001410289
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39813
FILM NUMBER: 231175486
MAIL ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TriSalus Life Sciences, Inc.
CENTRAL INDEX KEY: 0001826667
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 853009869
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6272 WEST 91ST AVENUE
CITY: WESTMINSTER
STATE: CO
ZIP: 80031
BUSINESS PHONE: 415 336 8917
MAIL ADDRESS:
STREET 1: 6272 WEST 91ST AVENUE
CITY: WESTMINSTER
STATE: CO
ZIP: 80031
FORMER COMPANY:
FORMER CONFORMED NAME: MedTech Acquisition Corp
DATE OF NAME CHANGE: 20200930
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-08-10
0
0001826667
TriSalus Life Sciences, Inc.
TLSI
0001410289
Szela Mary T
6272 W. 91ST AVENUE
WESTMINSTER
CO
80031
1
1
0
0
CEO and President
Common Stock
279963
D
Employee Stock Option (right to buy)
1.22
2028-01-29
Common Stock
177973
D
Employee Stock Option (right to buy)
0.41
2030-10-05
Common Stock
17302
D
Employee Stock Option (right to buy)
0.41
2031-04-20
Common Stock
101345
D
Employee Stock Option (right to buy)
2.43
2031-11-02
Common Stock
216287
D
Employee Stock Option (right to buy)
2.43
2032-04-19
Common Stock
55616
D
Employee Stock Option (right to buy)
10.30
2033-05-18
Common Stock
58409
D
The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming a director and an executive officer of the Issuer. The Reporting Person was appointed as a director and an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).
Includes 36,774 shares issued pursuant to a restricted stock unit award ("RSU"). The RSU vests in four equal annual installments commencing on October 5, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
The shares subject to this stock option became fully vested on January 22, 2022.
The shares subject to this stock option vest in 48 equal monthly installments from the vesting commencement date of October 1, 2020, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Twenty-five percent of the shares subject to the option vested on November 3, 2022, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Seventy-five percent of the shares subject to this stock option vests on April 20, 2025, the third anniversary of the vesting commencement date, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Twenty-five percent of the shares subject to the option vests on May 19, 2024, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
/s/ Mary Szela
2023-08-14
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Sean Murphy of TriSalus Life Sciences, Inc. (the "Company") and Alla
Kagan of Cooley LLP, signing individually, as the undersigned's true and lawful
attorneys-in fact and agents to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or greater than 10% stockholder of the Company,
Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Forms 3, 4 or 5
(including any amendments thereto) and timely file such forms with the U.S.
Securities and Exchange Commission and any stock exchange or similar authority;
and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by the Company
or employed by or a partner at Cooley LLP, as applicable.
The undersigned has caused this Power of Attorney to be executed as of July 20,
2023.
Mary Szela
/s/ Mary Szela
(Signature)